N/A
N=245
Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
Covid19 · Sars-CoV-2 Infection
Bottom Line
View on ClinicalTrials.gov: NCT05119348 ↗Enrolled (actual)
245
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcome: Primary: SARS-CoV-2 Infection — 4; 2 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- STOPCOV (Other)
- Age
- Pediatric, Adult, Older Adult · 12+ yrs
- Sex
- All
- Sponsor
- Desmond Tutu HIV Foundation
- Primary completion
- Aug 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY SARS-CoV-2 Infection |
4; 2 | — |
| SECONDARY COVID19 Symptoms |
11; 9 | — |
Summary
South Africa recorded it's first coronavirus disease 2019 (COVID19) case on March 5, 2020. In response to the COVID19 outbreak World Health Organisation recommendations, South Africa implemented non-pharmaceutical recommendations. The major risk mitigation factors recommended by World Health Organisation and others - physical distancing and hygiene - are extremely difficult to implement in much of Africa. The investigators will conduct a randomised controlled trial to investigate the effect of an infection mitigation intervention to assess the effect on household transmission of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 in household settings with an index patient diagnosed SARS-CoV-2 positive.
Eligibility Criteria
Inclusion Criteria
- recently diagnosed SARS-CoV-2 positive
- Individual >12 years
- Able to give assent if 18 years
- Self-isolating at home at the time of COVID diagnosis
Exclusion Criteria
- <12 years
- Unable to give consent
Data sourced from ClinicalTrials.gov (NCT05119348). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.